HomeBUSINESS
BUSINESS

Daiichi Sankyo Begins PII Study of DS-8201 for Gastric Cancer in Japan, South Korea
(Nov.22.2017)

Daiichi Sankyo said on November 21 that it has begun the administration of its investigational antibody drug conjugate (ADC) DS-8201 (development code) in patients with advanced gastric cancer in a multinational PII study in Japan and South Korea ...
(LOG IN FOR FULL STORY)

News Calendar